PARPi and NHA combination therapy for patients with mCRPC – a US and EU perspective

COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro, Medical Oncologist at Hospital Universitario 12 de Octubre in Madrid, discuss clinical implementation of PARP inhibitors and novel hormonal agent (NHA) combinationtherapy for patients with mCRPC, providing both a US and EU perspective. In this podcast, the experts discuss efficacy and safety data from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and data from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in a biomarker positive mCRPC population. The experts discuss the differing trial results and how these compare to the TALAPRO-2 trial of talazoparib plus enzalutamide. They discuss the value of genetic testing considering these results and debate whether an all-comer mCRPC patient population should be treated with a PARP inhibitor plus NHA combination or whether treatment should be determined based on HRR alterations.  The experts consider how this combination therapy may be implemented in clinical practice in the future including how to manage patients who are already receiving a NHA prior to becoming castration resistant.

There are no comments yet.

Please log in to write the first comment.